FDA accepts 510(k) premarket notification filing for Xen treatment system

The FDA has accepted the filing of the 510(k) premarket notification application for the Xen Glaucoma Treatment System, Allergan announced in a press release. The system includes the Xen45, which is a minimally invasive gelatin shunt, and the Xen injector.